Summary
Following the identification of a synergistic antitumor effect in a murine model, the combination of etoposide and vincristine has been explored in the clinic. Etoposide was given at 4 dose levels (250, 500, 750 or 1,000 mg/m2) with each dose given in 3 equal fractions daily for 3 days. The dose of vincristine was fixed (two 0.75 mg infusions over 22 hours each between doses of etoposide). A total of 26 patients were entered into study and 7, 11, 10 and 5 patients were treated at the 250, 500, 750, and 1,000 mg/m2 dose levels, respectively. Myelosuppressioh was the principle side effect and Grade 4 WBC toxicity (< 1,000/mm3) developed in 14%, 27%, 40% and 40%, respectively, of the patients treated at each of these respective dose levels. Life-threatening infections occurred in 0%, 9%, 30% and 60% of the patients at these levels, respectively. Reversal of marrow toxicity was rapid with repeat courses given at 3-week intervals. Non-hematologic toxicity, including neurotoxicity, nausea, vomiting, and mucositis was generally mild when present. Objective responses were observed in 1 patient each with refractory Hodgkin's disease and immunoblastic lymphoma. Prolonged periods of stable disease occurred in 2 patients with adenocarcinoma of the lung and one patient with Hodgkin's disease. The starting dose of etoposide recommended for further trials of this agent in combination with infusion of vincristine is 500 mg/m2 given in fractionated doses; dose escalation should be possible in many patients.
Similar content being viewed by others
References
Jackson Jr DV, Bender RA: The clinical pharmacology of the vinca alkaloids, epipodophyllotoxins, and maytansine. In: H.M. Pinedo (ed) Clinical Pharmacology of AntiNeoplastic Drugs, New York, NY; Elsevier/North-Holland, Biomedical Press B.V., 277–294, 1978
Radice PA, Bunn Jr PA, Ihde DC: Therapeutic trials with VP-16–213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 63: 1231–1239, 1979
Taylor RE, McElwain TJ, Barrett A, Peckham MJ: Etoposide as a single agent in relapsed advanced lymphomas: a phase II study. Cancer Chemother Pharmacol 7: 175–177, 1982
Jackson Jr DV, Long TR, Trahey TT, Morgan TM: Synergistic antitumor activity of vincristine and VP-16–213. Cancer Chemother Pharmacol 13: 176–180, 1984
Jackson Jr DV, Long TR, Rice DG, Morgan TM: Combination of vincristine and VP-16–213: Evaluation of drug sequence. Cancer Biochem Biophys 8: 265–275, 1986
Johnson DH, Wolff SN, Hande JD, Hainsworth MF, Fer MF, Greco FA: High-dose VP-16–213 (HDE) treatment of extensive small cell lung cancer (SCC) (Abstr) Proc Am Soc Clin Oncol 2: 193, 1983
Johnson DH, Hande KR, Hainsworth JD, Greco FA: High dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 67: 957, 1983
Wolff SN, Fer MF, McKay CM, Hande KR, Hainsworth JD, Greco FA: High dose VP-16–213 and autologous bone marrow transplantation for refractory malignancies: A phase I study. J Clin Oncol 1: 701–705, 1983
Postmus PED, Mulder NH, Sleifjer DT, Meinesz AF, Vriesendorp R, deVries EGE: High-dose etoposide for refractory malignancies: A phase I study. Cancer Treat Rep 68: 1471–1474, 1985
Jackson DV, Cruz JM, Zekan P, Spurr CL, White DR, Richards F II, Muss HB: Phase I study of vincristine and escalating doses of etoposide. Invest New Drugs, in press, 1988
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207, 1981
O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE: Drug therapy. Etoposide (VP-16–213). Current status of an active anticancer drug. N Engl J Med 312: 692–700, 1985
Jackson Jr DV, Wells HB, White DR, Muss HB, Richards F II, Cooper MR, Stuart JJ, Pope EK, Spurr CL: Lack of penetration of vincristine induced neurotoxicity by VP-16–213. Am J Clin Oncol 6: 326–330, 1983
Thant M, Hawley J, Smith MT, Cohen MH, Minna JD, Bunn PA, Ihde DC, West W, Matthews MJ: Possible enhancement of vincristine neuropathy by VP-16. Cancer 49: 859–864, 1982
Jackson DV, Castle MC, Bender RA: Biliary excretion of [3H]-vincristine in man. Clin Pharmacol Ther 24: 101–107, 1978
Hande KR, Wedlund PJ, Noone RM: Pharmacokinetics of high-dose etoposide (VP-16–213) administered to cancer patients. Cancer Res 44: 379–382, 1984
Dombbernowsky P, Nissen NI: Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16–213 (NSC-141540) in L1210 leukemia. Acta Path Microbiol Scan 5: 715–724, 1973
Jackson DV, Bender RA: Cytotoxic thresholds of vincristine in a murine and human leukemia cell line in vitro. Cancer Res 39: 4346–4349, 1979
Jackson DV: Periwinkle alkaloids II: vincristine. In: J.J. Lockich (ed) Cancer Chemotherapy by Infusion, pp 181–199. Chicago, IL: Precept Press, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jackson, D.V., Cruz, J.M., White, D.R. et al. Combination high-dose etoposide and vincristine infusion. Invest New Drugs 8 (Suppl 1), S59–S64 (1990). https://doi.org/10.1007/BF00171985
Issue Date:
DOI: https://doi.org/10.1007/BF00171985